

# United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address. COMMISSIONER FOR PATENTS PO Box 1450 Alexandria, Virginia 22313-1450 www.uspto gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/980,263	03/21/2002	Hermona Soreq	2391-00101	1307
7:	590 07/22/2003			
Kenneth I Kohn Kohn & Associates 30500 Northwestern Highway suite 410			EXAMINER	
			WEGERT, SANDRA L	
Farmington Hills, MI 48334			ART UNIT	PAPER NUMBER
			1647	11
			DATE MAILED: 07/22/2003	1/

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary  The MAILING DATE of this communication Period for Reply	EPLY IS SET TO EXPIRE <u>1</u> MO	SOREQ ET AL.  Art Unit  1647  th the correspondence address			
The MAILING DATE of this communication	Sandra Wegert  appears on the cover sheet with  EPLY IS SET TO EXPIRE 1 MG	1647			
	appears on the cover sheet with				
	EPLY IS SET TO EXPIRE <u>1</u> MO	th the correspondence address			
Period for Reply					
A SHORTENED STATUTORY PERIOD FOR R	ON.	ONTH(S) FROM			
<ul> <li>THE MAILING DATE OF THIS COMMUNICATION</li> <li>Extensions of time may be available under the provisions of 37 Claster SIX (6) MONTHS from the mailing date of this communication</li> <li>If the period for reply specified above is less than thirty (30) days.</li> <li>If NO period for reply is specified above, the maximum statutory properties to reply within the set or extended period for reply will, by</li> <li>Any reply received by the Office later than three months after the earned patent term adjustment. See 37 CFR 1.704(b).</li> </ul>	FR 1.136(a). In no event, however, may a rein.  a reply within the statutory minimum of thirty eriod will apply and will expire SIX (6) MON' statute, cause the application to become AB	y (30) days will be considered timely. THS from the mailing date of this communication. ANDONED (35 U.S.C. § 133)			
Status					
1) Responsive to communication(s) filed on	<u>16 May 2002</u> .				
2a) ☐ This action is <b>FINAL</b> . 2b) ☐	This action is non-final.				
3) Since this application is in condition for a closed in accordance with the practice up	llowance except for formal mat nder <i>Ex parte Quayle</i> , 1935 C.I	tters, prosecution as to the merits is D. 11, 453 O.G. 213.			
Disposition of Claims  4)   Claim(s) 1-15 is/are pending in the applic	ation				
, — · · · · · · · · · · · · · · · · · ·	ndrawn from consideration.				
4a) Of the above claim(s) is/are wit 5) ☐ Claim(s) is/are allowed.	Idiawii iloiti collaideradon.				
6) Claim(s) is/are rejected.					
7) Claim(s) is/are rejected.					
8) Claim(s) 1-15 are subject to restriction an	d/or election requirement				
Application Papers	a, or orderer requirement.				
9) The specification is objected to by the Exa	miner.				
10) The drawing(s) filed on is/are: a)	accepted or b) objected to by t	he Examiner.			
Applicant may not request that any objection	to the drawing(s) be held in abeya	ance. See 37 CFR 1.85(a).			
11) The proposed drawing correction filed on _	is: a)□ approved b)□ d	isapproved by the Examiner.			
If approved, corrected drawings are required	in reply to this Office action.				
12) The oath or declaration is objected to by the	e Examiner.				
Priority under 35 U.S.C. §§ 119 and 120					
13) Acknowledgment is made of a claim for fo	reign priority under 35 U.S.C.	§ 119(a)-(d) or (f).			
a) ☐ All b) ☐ Some * c) ☐ None of:					
1. Certified copies of the priority docu	ments have been received.				
2. Certified copies of the priority docu	2. Certified copies of the priority documents have been received in Application No				
3. Copies of the certified copies of the application from the Internation  * See the attached detailed Office action for	al Bureau (PCT Rule 17.2(a)).				
14) Acknowledgment is made of a claim for do					
a) The translation of the foreign language					
15) Acknowledgment is made of a claim for do					
Attachment(s)					
<ol> <li>Notice of References Cited (PTO-892)</li> <li>Notice of Draftsperson's Patent Drawing Review (PTO-94</li> <li>Information Disclosure Statement(s) (PTO-1449) Paper N</li> </ol>	8) 5) Notice of I	Summary (PTO-413) Paper No(s) Informal Patent Application (PTO-152)			

### **DETAILED ACTION**

#### **Election/Restriction**

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in response to this action, to elect a single invention to which the claims must be restricted.

- 1. Claims 1-5, drawn to an antibody.
- II. Claims 6-16, drawn to a method of diagnosing a condition or disease using an antibody.

The inventions are distinct, each from the other because of the following reasons:

The first claimed invention lacks a special technical feature because it fails to distinguish the claimed invention from the prior art (e.g., Boschetti, et al. 1996, Clinical Chem., 42(1): 19-23). The prior art discloses an antibody against a splice variant of the C-terminal of acetylcholinesterase, (see, for example: page 22, Discussion). This meets the limitations of the antibody recited in the first claimed invention. Therefore, none of the other claimed inventions can share a special technical feature with the first claimed invention.

Application/Control Number: 09/980,263

Art Unit: 1647

Inventions I and II are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the antibody can be used to immunoprecipitate the protein of interest; as well, the polypeptide can be detected by means of an RNA probe/detection system.

#### **Election/Restriction**

Furthermore, a second restriction is required under 35 U.S.C. 121 and 372 as follows:

If applicant elects from Inventions I or II (above), one disease or condition must also be selected to be considered responsive:

- i. central nervous system stress.
- ii. disruption of the blood-brain-barrier.
- iii. Alzheimer's disease,
- iv. head injury.
- v. head trauma,
- vi. exposure to irradiation,
- vii. exposure to insecticide, or
- viii. [exposure to] nerve gas.

Application/Control Number: 09/980.263

Art Unit: 1647

### **Election/Restriction**

Furthermore, a third restriction is required under 35 U.S.C. 121 and 372 as follows:

If applicant elects from Inventions I or II (above), one SEQ ID NO must also be selected to be considered responsive:

- A) SEQ ID NO: 1,
- B) SEQ ID NO: 2, or
- C) SEQ ID NO: 3.

Inventions i-viii are independent and distinct, each from the other, because the methods for their diagnosis are practiced with materially different process steps for materially different purposes and each method requires a non-coextensive search because of different starting materials, process steps, patients, medical personnel and goals.

The products of Invention A)-C) are patentably distinct from each other because they have different putative functions, different structures, and require completely different search terms, starting points and strategies.

Application/Control Number: 09/980,263

Art Unit: 1647

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, separate search requirements, and different classification, restriction for examination purposes as indicated is proper.

Applicant is advised that in order for the reply to this requirement to be complete, it must include an election of the invention to be examined even though the requirement be traversed (37 C.F.R. 1.143)

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 C.F.R. 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 C.F.R. 1.48(b) and by the fee required under 37 C.F.R. 1.17(i).

## Advisory information

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Sandra Wegert whose telephone number is (703) 308-9346. The examiner can normally be reached Monday - Friday from 9:30 AM to 6:00 PM (Eastern Time).

Art Unit: 1647

If attempts to reach the examiner by telephone are unsuccessful, the Examiner's supervisor. Gary Kunz, can be reached at (703) 308-4623.

Official papers filed by fax should be directed to (703) 308-4242. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-0196.

Etyabet C. Bennineres

ELIZABETH KEMMERER PRIMARY EXAMINER

SLW

7/14/03